Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
Biocartis forum geopend
Volgen
Hi FL, police investigation excluded malicious intent. How they came to this conclusion I don't know. The insurance company will also look into detail before starting to pay off the damage. We are awaiting feedback from management on the fire impact, ML2, US approvals, etc.. Maybe I should go to Mechelen and go see for myself what's going on :-)
ElTorro schreef op 22 september 2021 16:48 :
Hi FL, police investigation excluded malicious intent. How they came to this conclusion I don't know. The insurance company will also look into detail before starting to pay off the damage.
We are awaiting feedback from management on the fire impact, ML2, US approvals, etc..
Maybe I should go to Mechelen and go see for myself what's going on :-)
Hi El Torro, I recall hearing the same but thought something more might be released. I'm uncertain how you can exclude malicious intent without identifying the source of the fire. Regards FL
ML 2 heropgestart,nu de rest nog
PERSBERICHT: Persbericht Biocartis Group NV: Biocartis kondigt heropstart aan van haar hoge-volume cartridge productielijn PERSBERICHT: 23 september 2021, 07:00 CEST Biocartis kondigt heropstart aan van haar hoge-volume cartridge productielijn Mechelen, België, 23 september 2021 -- Biocartis Group NV (de 'Vennootschap' of 'Biocartis'), een innovatief bedrijf in de moleculaire diagnostiek (Euronext Brussels: BCART), kondigt vandaag de heropstart van haar hoge-volume cartridge productielijn 'ML2' aan. Na een bra www.globenewswire.com/Tracker?data=_H... n www.globenewswire.com/Tracker?data=p6... d www.globenewswire.com/Tracker?data=SX... die uitbrak in een van de opslagfaciliteiten van het bedrijf in Mechelen (België) in de nacht van 30 juli 2021, werd de productie van de ML2-lijn tijdelijk opgeschort omdat structurele herstellingen aan het gebouw en bepaalde ondersteunende systemen nodig waren. Deze herstellingen, alsook verschillende daaropvolgende controle- en kwaliteitsgerelateerde procedures, werden eerder deze week voltooid. Dit leidde tot de succesvolle herstart van de ML2-lijn in de nacht van 21 september 2021. Herman Verrelst, Chief Executive Officer van Biocartis, reageerde: "Ik ben zeer verheugd te kunnen aankondigen dat vanaf vandaag de commerciële productie van cartridges op de ML2-lijn is hervat. Onze teams hebben enorm hard gewerkt om de ML2-lijn weer operationeel te krijgen na het brandincident. We kunnen trots zijn op deze prestatie die de sterkte en veerkracht van onze teams laat zien." Eerder deze maand, op 2 september 2021 bij de aankondiging van haar H1 2021 resultaten, had Biocartis haar 40% cartridgevolume groeidoelstelling voor 2021 bevestigd, echter onder voorbehoud van de herstart van de ML2-lijn en de tijdige beschikbaarheid van reagentia grondstoffen voor Idylla(TM) cartridges in voldoende hoeveelheden. Nu de ML2-lijn opnieuw is opgestart, blijft de Vennootschap inspanningen leveren om de levering van bepaalde test-specifieke reagentia veilig te stellen, om de volledige capaciteit van de ML2-lijn te kunnen benutten en om de potentiële tijdelijke onbeschikbaarheid van bepaalde Idylla(TM) producten te minimaliseren. ----- EINDE ---- Meer informatie: Renate Degrave Hoofd Corporate Communications & Investor Relations Biocartis e-mail rdegrave@biocartis.comhttps ://www.globenewswire.com/Tracker?data=DZPciWeI2qAp-Bcdot2VyKIibeMN3tTuyE8IvasHxzM-cI2BLHEtgsuXa-O7GcHXb0GAOWamk5aGUKIHCa3o2rZ9ofliACghIlBIE7C9i7o= tel +32 15 631 729 gsm +32 471 53 60 64
ben tevreden voor jullie dat ze terug opgestart is
Hopende schreef op 23 september 2021 07:58 :
ben tevreden voor jullie dat ze terug opgestart is
En wij zijn tevreden dat jij tevreden bent :)
'Prognose Biocartis is redelijk' Analist Thomas Vranken reageert op het nieuws van de diagnosticaspeler Biocartis dat het de ML2-productielijn weer heeft herstart (zie post 7u21). 'De herstart bevestigt dat de apparatuur geen kritische schade heeft opgelopen. Maar we hadden ook niet verwacht dat een disfunctionele productielijn de grootste flessenhals was voor het bedrijf op de korte termijn.' 'Want de brand heeft vooral een ravage aangericht bij de voorraad reagentia', vervolgt de analist. 'Die zijn vermoedelijk een stuk moeilijker om te vervangen. Want de wereldwijde tekorten van testmaterialen zal door de pandemie waarschijnlijk voortduren in de komende maanden.' Maar Vranken denkt dat de prognose van het bedrijf - 40 procent groei in cartridgevolumes voor 2021 - redelijk is. 'Dat cijfer ligt binnen de marges van de mogelijkheden, gegeven de indrukwekkende expansie van 96 procent in de eerste jaarhelft, wanneer de reagentia tijdelijk geleverd worden.' De analist blijft bij zijn koopadvies en koersdoel van 7 euro. Het aandeel wint 2,8 procent.www.tijd.be/markten-live/live-blog/po...
Stockbrood schreef op 23 september 2021 08:42 :
[...]
En wij zijn tevreden dat jij tevreden bent :)
;) ik ben iemand dat iemand anders alles gunt , maar zijn op forums veel andere
Advies van KBC Securities over Biocartis Beurshuis KBC Securities Aandeel Biocartis Group Datum 23 september 2021 Advies Kopen Koersdoel 7,00 EUR Detail advies BRUSSEL (Trivano.com) - Op 23 september 2021 hebben de analisten van KBC Securities hun beleggingsadvies voor Biocartis Group (BCART; ISIN: BE0974281132) herhaald. Het advies van KBC Securities voor Biocartis Group blijft "kopen". De analisten behouden hun koersdoel van 7,00 EUR. Op 25 februari 2021 publiceerde Biocartis Group zijn jaarresultaten.
Hopende schreef op 23 september 2021 10:18 :
[...]
;) ik ben iemand dat iemand anders alles gunt , maar zijn op forums veel andere
Wanneer koop je je verkochte stukjes terug? Rond 5 euro ?
It was a close call by they succeeded in getting the ML2 operational again. I hope management realizes there is no longer margin for errors.
ElTorro schreef op 23 september 2021 16:53 :
It was a close call by they succeeded in getting the ML2 operational again.
I hope management realizes there is no longer margin for errors.
Don't over react. Let's be honest... They didn't want the fire as well. Let's give them some credit. I don't think anyone of us would have done differently. They communicated the fire and theirplanned action as well as a timing. They fulfilled Al the promises they made. They should get kudo's for the way they communicated and acted on the fire incident .
StiMO schreef op 23 september 2021 11:51 :
[...]
Wanneer koop je je verkochte stukjes terug? Rond 5 euro ?
Ik blijf eraf , maar blijf het volgen
Stockbrood schreef op 23 september 2021 19:40 :
[...]
Don't over react. Let's be honest... They didn't want the fire as well. Let's give them some credit. I don't think anyone of us would have done differently. They communicated the fire and theirplanned action as well as a timing. They fulfilled Al the promises they made.
They should get kudo's for the way they communicated and acted on the fire incident .
Stockbrood While I'm glad they have re-established ML-2 operations, it remains to be seen whether it is constrained in any way by the stock of reagents they were able to assemble. Potential exists that some assays may still be affected by different suppliers etc. We'll have to wait for additional updates. I've resigned my self that my 2022 decision time frame is likely to be impeded by the fire. The 2nd half 2021 will not be representative of gross margins since ML2 was off line. That means we will not get a real data point for almost a year. Regards FL
Hi Stockbrood. Of course I'm not talking about the fire, they handled this one very well, and you can see the market appreciating this. Trust, it’s all about trust. In the course off recent years it seems they have lost this little by little, due to certain decisions they made and the way of communicating. What I’m saying is that they have to see this point as a fresh start to build out a positive story and making sure that the point of profit is within the near future (as promised 2 years ago). And in this story the margin for error is very small now. Because as you know, trust comes on foot, but leaves on horseback.
ElTorro schreef op 24 september 2021 09:15 :
Hi Stockbrood.
Of course I'm not talking about the fire, they handled this one very well, and you can see the market appreciating this. Trust, it’s all about trust. In the course off recent years it seems they have lost this little by little, due to certain decisions they made and the way of communicating.
What I’m saying is that they have to see this point as a fresh start to build out a positive story and making sure that the point of profit is within the near future (as promised 2 years ago). And in this story the margin for error is very small now. Because as you know, trust comes on foot, but leaves on horseback.
I agree. Let the acceleration begin :)
Check out this new article discussing use of Idylla titled, Frequency of microsatellite instability (MSI) in upper tract urothelial carcinoma: comparison of the Bethesda panel and the Idylla MSI assay in a consecutively collected, multi-institutional cohort. Highlight this bit in discussion section. "In this investigation, with the Idylla MSI Assay, a new, innovative easy to use and time-saving approach for MSI diagnostics was tested for UTUCs. To date, the newly designed marker set, consisting of seven mononucleotides, is clinically validated and applied for diagnostic use for colorectal cancer and is ongoing for verification of endometrial carcinoma.32 In our study of 243 UTUCs, we observed a high concordance of 98.35% of MSI testing between the two methods. These concordance rates are comparable with those of colorectal cancer. Compared with standard diagnostics, we propose that the Idylla MSI Assay is a more robust methodology with a lower invalid rate. Nine vs five invalid results were detected using standard method compared with the Idylla MSI Assay, respectively. Additional reasons for implementing the Idylla MSI Assay into routine laboratory testing are: (1) the turnaround time was shortened significantly to approximately 3?hours compared with a workload of 2?days using the NCI method and (2) implementing a fully automated analysis system as well as a reduction of preanalytical steps also significantly reduces human resources. Therefore, our study could determine that the same marker panel, applied for colorectal cancer samples, is transferable to UTUC with a high concordance to current established testing methods."
Oz Thanks for posting the info. UTUCs are fairly rare and I'm not sure if shaving a couple days off of the results TAT has significant impact on the treatment and/or the prognosis. But as you posted, the ability to recover actionable results in cases where the immunohistochemistry failed to yield results should be very relative as is the fact that Idylla requires significantly less tachnician time and effort. I consider Promega the primary MSI competitor since they are aligned with Merk as a CDx for Keytruda, Their 510K review looks like it took about 8 months, so hopefully BCART has a positive determination by years end.www.accessdata.fda.gov/cdrh_docs/pdf2... FL www.accessdata.fda.gov/cdrh_docs/pdf2...
Besides the weakness in the overall markets we are still dealing with the glass half full scenario that Biocartis has presented us for the past few years. On one hand I can identify several macro conditions that should represent a substantial tailwind: 1) Pent up MDx backlog from all the proceedures and oncology testing that were delayed due to pandemic concerns; 2) The Idylla social distancing and testing on demand testing advantages as the market emerges from the pandemic; 3) It looks like global growth is slowing at the same time commomdity and labor costs are increasing. This could lead to stagflation. Idylla is well situated for labs seeking to constrain costs to maintain margins since the system requires minimal operator/technician time; and 4) Studies have indicated a trend toward decentralization of MDx testing (moving closer to patient and point of care). On the other hand the we have familiar concerns that have dogged the shareprice for years: 1) lengthy timeframes for registration approvals outside of the EU; 2) Cost structure and bloat that hinder margin improvement and a move towards profitability; 3) Execution/communication breakdowns (fire, handling of GHDX collaboration dissolution etc); 4) Dwindling cash and convertible debt. I could go on and on for both lists. The point is that the Oncology MDx market is fragmented and no one firm controls dominant market share, The MDx market is growing at an estimated 20%/year rate. I see no reason why automation will not carve out a niche in this sector. Factors have aligned to provide BCART a tailwind. The question remains whether BCART can step up its execution to take advantage of these factors and compete. I was hoping that BCART could put together a good financial report before going into the next cash raise. Unfortunately, we will get few good data points to assess performance in the next year. I still think they should list in the US but the overall market is becoming less favorable. meticulousblog.org/top-10-companies-i... FL
Thx for your ever constructive input FL. I guess for the moment no news is good news, next point to assess the stock is 10 November. As you stated the macro conditions are becoming more and more unfavorable for startup investment shares so it seems. There are a lot of macro factors that could go right or wrong these days. BCART was unable to profit from the bull market the past years (pre- and post corona of course), due to some events you mentioned. Some events in the (near) future (US approvals for one) could turn it the other way and push the share towards safer grounds. So I’m still positive for the moment.
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)
Premium
Word nu abonnee van IEX en krijg onbeperkt toegang tot onze (koop)tips en succesvolle modelportefeuilles. Nu 3 maanden voor slechts €19,95! Profiteer van 58% korting!
Word abonnee